| Colorectal Carcinoma
Vectibix vs Braftovi
Side-by-side clinical, coverage, and cost comparison for colorectal carcinoma.Deep comparison between: Vectibix vs Braftovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBraftovi has a higher rate of injection site reactions vs Vectibix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Braftovi but not Vectibix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vectibix
Braftovi
At A Glance
IV infusion
Every 2 weeks
EGFR antagonist
Oral
Once daily
BRAF inhibitor
Indications
- Colorectal Carcinoma
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Colorectal Carcinoma (RAS Wild-Type mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) as monotherapy or in combination with FOLFOX.
Colorectal Carcinoma (KRAS G12C-Mutated mCRC) 6 mg/kg IV infusion every 14 days over 60 minutes (<=1000 mg) or 90 minutes (>1000 mg) in combination with sotorasib; administer first sotorasib dose prior to first Vectibix infusion.
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Rash, acneiform dermatitis, erythema, pruritus, dry skin, paronychia, diarrhea, stomatitis, mucosal inflammation, fatigue, asthenia, nausea, anorexia, hypomagnesemia, hypokalemia, musculoskeletal pain
Serious General physical health deterioration, intestinal obstruction, diarrhea, dehydration, sepsis, cardiac arrest
Postmarketing Skin necrosis, angioedema, bullous mucocutaneous disease, infusion reaction, keratitis, ulcerative keratitis, corneal perforation
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Pharmacology
Panitumumab is a fully human IgG2 monoclonal antibody that competitively blocks ligand binding to EGFR, inhibiting receptor autophosphorylation and downstream signaling, thereby inhibiting tumor cell growth and inducing apoptosis; in KRAS G12C-mutated mCRC, combining EGFR blockade with sotorasib overcomes EGFR-mediated resistance to KRAS G12C inhibition.
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vectibix
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Vectibix
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Vectibix
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VectibixView full Vectibix profile
BraftoviView full Braftovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.